Blue Jet Healthcare Limited (BLUEJET) reported a 22% QoQ increase in revenue for Q4 FY26, with PAT rising by 60%.
SMS Pharmaceuticals Limited (SMSPHARMA) reports FY26 PAT up 48% to ₹102 crore, driven by margin expansion and backward integration.
Fortis Healthcare Limited (FORTIS) announces Q4 FY26 results with consolidated revenues up 17.8% and PAT up 44.2%.
Zota Health Care Limited (ZOTA) reports strong FY26 results with revenue up 83.86% YoY, EBITDA at ₹2,597.73 lakhs, and expansion to 2,579 stores.
Torrent Pharmaceuticals Limited (TORNTPHARM) reports a 43% revenue increase in Q4 FY26, reaching ₹2,215 crore.
Lupin Limited (LUPIN) secures China approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market.
Shilpa Medicare Limited (SHILPAMED) reports Q4 FY26 earnings with revenue up 30% and EBITDA surging 40%.
Alembic Pharmaceuticals Limited (APLLTD) announces USFDA final approval for its Levothyroxine Sodium Tablets, expanding its generic drug portfolio.
Laxmi Dental Limited (NSE: LAXMIDENTL) announces Q4 FY26 results with 21.9% YoY revenue growth, PAT up 136.1%.
Aurobindo Pharma Limited (AUROPHARMA) announced consolidated financial results for Q4 and FY 2026, showing a 5.6% YoY revenue increase to INR 8,853 Cr.